Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies
暂无分享,去创建一个
David Nemazee | Joseph G. Jardine | Oleksandr Kalyuzhniy | Yumiko Adachi | William R. Schief | Andrew B. Ward | Fabian Sesterhenn | Xiaozhen Hu | Dennis R. Burton | Ian A. Wilson | Bryan Briney | Anita Sarkar | Michael Kubitz | Daniel W. Kulp | Xiaozhen Hu | D. Burton | I. Wilson | W. Schief | B. Briney | D. Nemazee | A. Ward | J. Jardine | O. Kalyuzhniy | Yumiko Adachi | G. Ozorowski | D. Sok | S. Menis | Meaghan Jones | N. de Val | Gabriel Ozorowski | Devin Sok | Sergey Menis | Erik Georgeson | Erik Georgeson | M. Kubitz | Karen L Saye-Francisco | A. Sarkar | A. Ramos | Bryan S. Briney | Khoa Le | F. Sesterhenn | S. Spencer | Khoa M. Le | Meaghan Jones | Karen L. Saye-Francisco | Alejandra Ramos | Natalia de Val | Patrick Skog | Ronald Jacak | Tanya R. Blane | Skye Spencer | Patrick D. Skog | Tanya Blane | Ronald Jacak | Natalia de Val
[1] Jerome H. Kim,et al. Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies , 2014, Journal of Virology.
[2] Tongqing Zhou,et al. Structure and immune recognition of trimeric prefusion HIV-1 Env , 2014, Nature.
[3] Michel C Nussenzweig,et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.
[4] Han Gao,et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. , 2014, Cell reports.
[5] D. Richman,et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[6] Joseph G. Jardine,et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen , 2016, Science.
[7] C Oseroff,et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. , 1994, Immunity.
[8] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[9] Young Do Kwon,et al. Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo , 2014, Journal of Virology.
[10] Barney S. Graham,et al. Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 , 2011, Journal of Virology.
[11] Thomas B Kepler,et al. B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study , 2012, Nature Biotechnology.
[12] Cinque S. Soto,et al. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors , 2015, Cell.
[13] Chaim A. Schramm,et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.
[14] Holly Janes,et al. Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.
[15] D. Dimitrov. Therapeutic antibodies, vaccines and antibodyomes , 2010, mAbs.
[16] N. Haigwood,et al. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens , 2016, The Journal of Immunology.
[17] D. Burton,et al. Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. , 2015, Immunity.
[18] B A McKinney,et al. High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals , 2012, Genes and Immunity.
[19] M. Nussenzweig,et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia , 2013, Nature.
[20] Daniel G. Brown,et al. PANDAseq: paired-end assembler for illumina sequences , 2012, BMC Bioinformatics.
[21] James E. Crowe,et al. Location and length distribution of somatic hypermutation-associated DNA insertions and deletions reveals regions of antibody structural plasticity , 2012, Genes and Immunity.
[22] David Nemazee,et al. Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.
[23] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[24] B. Haynes,et al. HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.
[25] Chaim A. Schramm,et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.
[26] R. Koup,et al. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know , 2004, Nature Medicine.
[27] Ron Diskin,et al. Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies , 2013, The Journal of experimental medicine.
[28] Dennis R Burton,et al. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. , 2016, Annual review of immunology.
[29] L. Stamatatos,et al. Engineering, Expression, Purification, and Characterization of Stable Clade A/B Recombinant Soluble Heterotrimeric gp140 Proteins , 2011, Journal of Virology.
[30] Ron Diskin,et al. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120 , 2012, Proceedings of the National Academy of Sciences.
[31] Gwo-Yu Chuang,et al. Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline , 2014, The Journal of Immunology.
[32] L. Stamatatos,et al. Correction: Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs , 2013, PLoS Pathogens.
[33] John P. Moore,et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex , 2014, Proceedings of the National Academy of Sciences.
[34] John P. Moore,et al. Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[35] Mario Roederer,et al. Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.
[36] Dennis R. Burton,et al. Clonify: unseeded antibody lineage assignment from next-generation sequencing data , 2016, Scientific Reports.
[37] David Nemazee,et al. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen , 2015, Science.
[38] J. Hoxie,et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor , 2014, Science Translational Medicine.
[39] Michael S. Seaman,et al. Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.
[40] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[41] Young Do Kwon,et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. , 2013, Immunity.
[42] L. Stamatatos,et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.
[43] Ron Diskin,et al. Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design , 2011, Science.
[44] Renate Kunert,et al. Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.
[45] Marcel Martin. Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .
[46] L. Stamatatos,et al. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies , 2014, Science.
[47] D. Burton,et al. Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design , 2016, PLoS pathogens.
[48] J. Mascola,et al. Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. , 2016, Immunity.
[49] Jerome H. Kim,et al. HIV-1 vaccines , 2014, Human vaccines & immunotherapeutics.
[50] John P. Moore,et al. HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. , 2016, Trends in immunology.
[51] L. Stamatatos,et al. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice , 2016, Nature Communications.
[52] Michael S. Seaman,et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 , 2015, Nature.
[53] Robyn L Stanfield,et al. Antibody vs. HIV in a clash of evolutionary titans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[54] T. Kepler,et al. Envelope Deglycosylation Enhances Antigenicity of HIV-1 gp41 Epitopes for Both Broad Neutralizing Antibodies and Their Unmutated Ancestor Antibodies , 2011, PLoS pathogens.
[55] D. Dimitrov,et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens , 2009, Biochemical and Biophysical Research Communications.
[56] J. Mascola,et al. Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 , 2010, Journal of Virology.
[57] Lynn Morris,et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies , 2015, Nature Medicine.
[58] Alessandro Sette,et al. The optimization of helper T lymphocyte (HTL) function in vaccine development , 1998, Immunologic research.
[59] Wayne C Koff,et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. , 2014, Immunity.
[60] John P. Moore,et al. A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.
[61] Ron Diskin,et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.
[62] G. Debnath,et al. D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers , 2016 .
[63] Jonathan R. McDaniel,et al. Structures of HIV-1-Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design , 2015, Nature Structural &Molecular Biology.
[64] Mario Roederer,et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.
[65] Scott D Boyd,et al. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. , 2014, Cell host & microbe.
[66] John P. Moore,et al. Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.
[67] Mark Connors,et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.
[68] Xiping Wei,et al. Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.
[69] Tongqing Zhou,et al. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.